Cargando…
A systematic review on disease‐drug‐drug interactions with immunomodulating drugs: A critical appraisal of risk assessment and drug labelling
AIM: Use of immunomodulating therapeutics for immune‐mediated inflammatory diseases may cause disease‐drug‐drug interactions (DDDIs) by reversing inflammation‐driven alterations in the metabolic capacity of cytochrome P450 enzymes. European Medicine Agency (EMA) and US Food and Drug Administration (...
Autores principales: | de Jong, Laura M., Klomp, Sylvia D., Treijtel, Nicoline, Rissmann, Robert, Swen, Jesse J., Manson, Martijn L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9545038/ https://www.ncbi.nlm.nih.gov/pubmed/35484780 http://dx.doi.org/10.1111/bcp.15372 |
Ejemplares similares
-
Drug-Coated Balloon vs. Drug-Eluting Stent in Acute Myocardial Infarction: A Systematic Review and Updated Meta-Analysis
por: Fang, Zhen, et al.
Publicado: (2023) -
A Cocktail Interaction Study Evaluating the Drug‐Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels
por: Treijtel, Nicoline, et al.
Publicado: (2019) -
Drug-Eluting Balloon versus New-Generation Drug-Eluting Stent for the Treatment of In-Stent Restenosis: An Updated Systematic Review and Meta-Analysis
por: Cui, Kong-Yong, et al.
Publicado: (2018) -
Generic versus brand-name drugs used in cardiovascular diseases
por: Manzoli, Lamberto, et al.
Publicado: (2015) -
Mucoprotective drugs can prevent and treat nonsteroidal anti-inflammatory drug-induced small bowel enteropathy: a systematic review and meta-analysis of randomized controlled trials
por: Teutsch, Brigitta, et al.
Publicado: (2021)